| Literature DB >> 33816347 |
Jiuxin Qu1, Zhao Cai2, Yumei Liu2, Xiangke Duan2, Shuhong Han2, Jihong Liu2,3, Yuao Zhu2, Zhaofang Jiang1, Yingdan Zhang2, Chao Zhuo4, Yang Liu3, Yingxia Liu1,5, Lei Liu1,5, Liang Yang2,6.
Abstract
Pseudomonas aeruginosa is a biofilm-forming opportunistic pathogen which causes chronic infections in immunocompromised patients and leads to high mortality rate. It is identified as a common coinfecting pathogen in COVID-19 patients causing exacerbation of illness. In our hospital, P. aeruginosa is one of the top coinfecting bacteria identified among COVID-19 patients. We collected a strong biofilm-forming P. aeruginosa strain displaying small colony variant morphology from a severe COVID-19 patient. Genomic and transcriptomic sequencing analyses were performed with phenotypic validation to investigate its adaptation in SARS-CoV-2 infected environment. Genomic characterization predicted specific genomic islands highly associated with virulence, transcriptional regulation, and DNA restriction-modification systems. Epigenetic analysis revealed a specific N6-methyl adenine (m6A) methylating pattern including methylation of alginate, flagellar and quorum sensing associated genes. Differential gene expression analysis indicated that this isolate formed excessive biofilm by reducing flagellar formation (7.4 to 1,624.1 folds) and overproducing extracellular matrix components including CdrA (4.4 folds), alginate (5.2 to 29.1 folds) and Pel (4.8-5.5 folds). In summary, we demonstrated that P. aeuginosa clinical isolates with novel epigenetic markers could form excessive biofilm, which might enhance its antibiotic resistance and in vivo colonization in COVID-19 patients.Entities:
Keywords: COVID-19; DNA methylation; Pseudomonas aeruginosa; biofilm; coinfection
Mesh:
Substances:
Year: 2021 PMID: 33816347 PMCID: PMC8010185 DOI: 10.3389/fcimb.2021.641920
Source DB: PubMed Journal: Front Cell Infect Microbiol ISSN: 2235-2988 Impact factor: 5.293
Bacteria strains and plasmid used in this study.
| Strains or plasmids | Relevant genotype and/or characteristics | Reference |
|---|---|---|
|
|
| ( |
|
| SCV Isolate 1 | This study |
|
| SCV Isolate 2 | This study |
|
| PAO1 | ( |
|
| PAO1 | ( |
|
| PAO1 | ( |
|
| PAO1 containing | This study |
|
| Isolate 1 containing | This study |
|
| Isolate 2 containing | This study |
|
| Plasmid carrying | ( |
Figure 1Phenotypic tests. (A) Colony morphologies of P. aeruginosa PAO1, LYSZa7 and LYSZa8; (B) Cyclic-di-GMP levels in P. aeruginosa PAO1, LYSZa7 and LYSZa8 measured by cdrA::gfp reporter assay; (C) Swimming motility (left plate) and swarming motility(right plate) of P. aeruginosa PAO1, LYSZa7 and LYSZa8; (D) Biofilm formation of P. aeruginosa PAO1, LYSZa7, and LYSZa8 quantified by CV staining, **p-value <0.05; (E) las and rhl quorum sensing expression measured by PAO1ΔlasIΔrhlI/P and PAO1ΔlasIΔrhlI/P reporter strains.
Figure 2Levels of the patient’s blood indices. (A) Counts of WBC, L and N during the course of hospitalization. The isolates were found over the period of the second immune peak. Red arrows indicate the isolation times of LYSZa7(day 21) and LYSZa8(day 31); (B) Levels of IL-6 (pg/ml), CRP (mg/L), and PCT (ng/ml) during the course of hospitalization. Orange arrows indicate the isolation times of LYSZa7(day 21) and LYSZa8(day 31).
Figure 4Circular plot. From the innermost, Circle 1: GC content; Circle 2: GC Skew; Circle 3: P. aeruginosa LYSZa7; Circle 4: P. aeruginosa PAO1; Circle 5: P. aeruginosa PA14 (virulent clinical isolate); Circle 6: P. aeruginosa PA34 (strain isolated from Keratitis patient); Circle 7: P. aeruginosa DK2 (Strain isolated from Cystic Fibrosis patient); Circle 8: P. aeruginosa Pa1207 (strain isolated from Bacteremia patient); Circle 9: Genomic Islands predicted with specific GIs of LYSZa7 highlighted in red; Circle 10: Antimicrobial resistance genes (ARGs).
Figure 3Phylogenetic tree constructed using whole genomes of LYSZa7 and 23 other P. aeruginosa laboratory, clinical and environmental strains selected from NCBI database. P. aeruginosa PAO1 was used as reference strain.
Genes methylated in LYSZa7 comparing to P. aeruginosa PAO1 and motif information. Type: type of R-M system.
| Type | Methyltransferase | Motif | Genes methylated* |
|---|---|---|---|
| Type III | M.PaeZa7II | CCCGAG |
|
| Type I | M.PaeZa7I | AGGNNNNNPTGT |
|
*Grep function in shell was used to match methylated genes and QS and biofilm related genes.
Figure 5Dissimilarity analysis of samples and Gene Orthology analysis of differentially expressed genes; (A) PCoA plot of P. aeruginosa PAO1, LYSZa7 and LYSZa8 by Bray Curtis dissimilarity; (B) Heatmap of PAO1, LYSZa7 and LYSZa8 based on euclidean clustering distance; (C) Gene Orthology Enrichment based on the significantly regulated genes (fold change ≧ 4, adjusted p-value < 0.05) in LYSZa7 comparing to those of PAO1.
Significantly regulated genes involved in virulence and biofilm formation in LYSZa7 comparing to P. aeruginosa PAO1 (fold change ≧ 2, FDR adjusted p-value < 0.05); means: normalized mean counts of the sample groups.
| Feature ID | Product | Fold change | Adjusted p-value | PAO1 Means | LYSZa7 Means |
|---|---|---|---|---|---|
|
| alginate biosynthesis protein Alg44 | 11.17 | 3.14E-47 | 26.0 | 277.9 |
|
| alginate biosynthesis protein Alg8 | 7.87 | 8.78E-57 | 53.3 | 389.8 |
|
| phosphomannose isomerase/guanosine 5’-diphospho-D-mannose pyrophosphorylase | 29.12 | 1.16E-75 | 47.9 | 1352.3 |
|
| GDP-mannose 6-dehydrogenase AlgD | 19.91 | 7.43E-60 | 56.3 | 1076.1 |
|
| Alginate production outer membrane protein AlgE precursor | 15.83 | 8.60E-64 | 25.1 | 393.2 |
|
| alginate o-acetyltransferase AlgF | 19.26 | 5.84E-56 | 14.5 | 322.3 |
|
| alginate o-acetyltransferase AlgI | 5.19 | 2.60E-23 | 47.9 | 226.6 |
|
| alginate o-acetyltransferase AlgJ | 17.14 | 2.28E-46 | 4.8 | 182.5 |
|
| alginate biosynthetic protein AlgK precursor | 14.33 | 8.76E-48 | 16.2 | 250.3 |
|
| poly(beta-d-mannuronate) lyase precursor AlgL | 14.69 | 1.29E-58 | 21.6 | 321.1 |
|
| alginate biosynthesis protein AlgX | 20.54 | 1.60E-59 | 10.8 | 308.2 |
|
| aminoglycoside response regulator | -318.93 | 1.25E-49 | 229.6 | 2.5 |
|
| flagellar hook-associated protein type 3 FlgL | -8.39 | 1.14E-72 | 1,319.7 | 173.3 |
|
| flagellin type B | -7.44 | 0.00E+00 | 33,619.2 | 6865.2 |
|
| flagellar capping protein FliD | -1,624.06 | 8.80E-207 | 6,412.3 | 5.7 |
| PA2771 | diguanylate cyclase with a self-blocked I-site, Dcsbis | -17.32 | 2.07E-06 | 348.4 | 20.4 |
| PA4625 | cyclic diguanylate-regulated TPS partner A, CdrA | 4.41 | 4.60E-17 | 971.8 | 5208.9 |
|
| PelD | 5.55 | 5.54E-35 | 104.8 | 561.9 |
|
| PelE | 4.80 | 6.62E-20 | 65.3 | 280.4 |
|
| PelF | 5.00 | 8.20E-27 | 88.6 | 414.8 |
|
| type 4 fimbrial precursor PilA | -961.48 | 1.61E-221 | 29,476.2 | 40.7 |
|
| O-antigen ligase, WaaL | -8.00 | 3.94E-10 | 545.0 | 71.8 |
|
| UDP-N-acetyl-d-glucosamine 6-Dehydrogenase | -1,275.14 | 1.09E-199 | 6,270.7 | 7.2 |
|
| UDP-2-acetamido-2-deoxy-d-glucuronic acid 3-dehydrogenase, WbpB | -1,832.88 | 2.71E-164 | 3,815.0 | 4.8 |
|
| UDP-2-acetamido-3-amino-2,3-dideoxy-d-glucuronic acid N-acetyltransferase, WbpD | -2,685.85 | 6.53E-163 | 1,683.3 | 3.4 |
|
| UDP-2-acetamido-2-dideoxy-d-ribo-hex-3-uluronic acid transaminase, wbpE | -2,156.03 | 6.33E-173 | 4,611.0 | 4.8 |
|
| LPS biosynthesis protein WbpG | -2,523.51 | 3.59E-141 | 4,083.4 | 4.2 |
|
| probable glycosyltransferase WbpH | -1,978.78 | 4.72E-166 | 2,238.8 | 3.7 |
|
| UDP-N-acetylglucosamine 2-epimerase WbpI | -2,058.27 | 6.90E-147 | 3,268.5 | 4.3 |
|
| probable glycosyl transferase WbpJ | -1,336.39 | 9.86E-162 | 1,523.7 | 4.3 |
|
| probable NAD-dependent epimerase/dehydratase WbpK | -1,800.55 | 2.03E-149 | 1,150.5 | 3.7 |
|
| glycosyltransferase WbpL | -1,912.92 | 3.51E-164 | 1,218.6 | 3.8 |
|
| O-antigen translocase | -638.58 | 3.01E-98 | 435.9 | 3.4 |
|
| B-band O-antigen polymerase | -6,615.39 | 2.54E-138 | 757.6 | 3.2 |
|
| O-antigen chain length regulator | -655.23 | 7.50E-152 | 1,113.7 | 4.5 |
|
| elastase LasB | 2.60 | 7.02E-06 | 4,484.2 | 15730.4 |
|
| rhamnosyltransferase chain A | 2.74 | 1.41E-14 | 592.2 | 1887.9 |
|
| rhamnosyltransferase chain B | 3.05 | 5.51E-16 | 294.8 | 940.1 |